Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase 4 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Carcinoma, Hepatocellular 12Parkinson Disease 4, Autosomal Dominant Lewy Body 8Melanoma 6Carcinoma, Renal Cell 6Neoplasms 5Neoplasm Metastasis 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Castration-Resistant Prostate Cancer 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × lenvatinib × Clear all
NCT06110793 2026-05-13

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
54 enrolled
Breast

Breast Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

National University Hospital, Singapore

Phase 1/2 Active not recruiting
40 enrolled
Breast

Breast Neoplasms

NCT06140576 2023-11-20

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Zhejiang Cancer Hospital

Phase 1/2 Not yet recruiting
58 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡